Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Iguratimod bone-protective effect in rheumatoid arthritis
ChiCTR1800015615Phase 4Not yet recruiting
- Sponsor
- Tianjin First Central Hospital
- Start
- May 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of iguratimod in rheumatoid arthritis (RA), sponsored by Tianjin First Central Hospital. Planned start May 2018; status: not yet recruiting.
02
Drugs
iguratimod
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on ChiCTR1800015615.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1800015615.